ArticleACS omega2026
Transition-Metal-Free One-Pot Synthesis of (Hetero)chalcones with Cysteine Protease Inhibitory Activity.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a new and efficient one-pot methodology for the synthesis of (hetero)-chalcones via direct C-H functionalization. The protocol employs directed organolithiation of aromatic and heteroaromatic substrates, followed by in situ formylation using inexpensive DMF, which not only serves as the formylating agent but also generates lithium dimethylamide as the base for the subsequent aldol condensation with (hetero)-aryl ketones. This transition-metal-free and additive-free approach enables the preparation of 23 chalcone derivatives with broad structural diversity, varying both aromatic and heteroaromatic units, in isolated yields up to 85%. To demonstrate the synthetic utility of the obtained chalcones, a model chalcone was further transformed into two different derivatives, including a pyrazole and a thioacetic acid derivative. The synthesized chalcones were evaluated through enzymatic inhibition assays against cysteine proteases papain and Cathepsin B (CatB), with compound
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.